Clinical Trials Logo

Clinical Trial Summary

The rate of obesity increases continuously in France as in many developing countries.The risk of cesarean delivery is increased in obese compared to normal-weight women and postpartum complications as infections, thromboembolic events and related maternal death, are more common among obese women who deliver by cesarean than both normal-weight women with caesarean deliveries and obese women with vaginal deliveries. Unfortunately, obesity is associated with a higher rate of failed induction requiring a cesarean delivery and especially in nulliparous. Methods of induction for obese women have to be improved to decrease the c-section rate but investigators should also be cautious on the type and dose of PG not to affect the neonatal wellbeing associated with uterine hyperstimulation. The aim of this study is to demonstrate the efficacy of the association of mechanical and pharmacological cervical ripening (balloon catheter plus 50 µg oral prostaglandin E1) versus pharmacological cervical ripening alone (50 µg oral prostaglandin E1) to reduce the rate of caesarean sections in nulliparous obese women.


Clinical Trial Description

The rate of obesity increases continuously in France as in many developing countries. In 2012, in the US, one third of all pregnant women were obese. The risk of cesarean delivery is increased in obese compared to normal-weight women and postpartum complications as infections, thromboembolic events and related maternal death, are more common among obese women who deliver by cesarean than both normal-weight women with caesarean deliveries and obese women with vaginal deliveries. Prevalence of post-term is increased in obese pregnant women and the rate of induction of labor is twice the rate of normal-weight women, 42% versus 23% in the 2010 French National Survey. Unfortunately, obesity is associated with a higher rate of failed induction requiring a cesarean delivery and especially in nulliparous. Methods of induction for obese women have to be improved to decrease the c-section rate but investigators should also be cautious on the type and dose of PG not to affect the neonatal wellbeing associated with uterine hyperstimulation. In a recent randomized clinical trial (RCT), the rate of c-section after labor induction in obese women was not increased in obese women compared to normal-weight women with balloon catheter but it was also increased with prostaglandin E2 (PGE2) and moreover with higher rate of uterine hyperstimulation. Recently, low dose of oral misoprostol (PGE1) has been showed to be the drug with the lowest rate of c-section after induction of labor in all women and balloon catheter to be associated with the lowest rate of hyperstimulation. Because safety of these two specific methods for induction of labor, a comparison 1 to 1 were done recently for induction of labor in singletons with comparable results. Very few studies have focused on induction of labor in obese women even if the rate of maternal and neonatal complications are higher. The efficacy of combining these two methods with different mechanism of induction have been showed recently but no study has been published today on obese women. Recently a trial have showed a shorter induction-delivery time with the combination (misoprostol-foley) for induction of labor in the whole population with less need of oxytocin during labor without more complications neither for the mother nor for the baby.An induction will be considered "failed" if at least 12 hours have elapsed since both rupture of membranes and use of a uterine stimulant and the patient remains in latent labor. The aim of this study is to demonstrate the efficacy of the association of mechanical and pharmacological cervical ripening (balloon catheter plus 50 µg oral prostaglandin E1) versus pharmacological cervical ripening alone (50 µg oral prostaglandin E1) to reduce the rate of caesarean sections in nulliparous obese women. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03435458
Study type Interventional
Source University Hospital, Toulouse
Contact
Status Terminated
Phase Phase 3
Start date June 26, 2020
Completion date February 2, 2023

See also
  Status Clinical Trial Phase
Completed NCT00530439 - Lifestyle and Pregnancy: The Clinical Effect of Lifestyle Intervention During Pregnancy in Obese Women N/A
Recruiting NCT03084120 - Effect of the Maternal Obesity and/or the By-pass on the Growth and the Nutritional Balance of the Child N/A
Recruiting NCT05207059 - Healthy Early Life Moments in Singapore N/A
Not yet recruiting NCT03913364 - Impact of B. Bifidum 900791 Intake on Breast Milk Characteristics of Obese Mothers N/A
Not yet recruiting NCT05986539 - Early Life Feeding Exposure and Infant Immune and Health Status.
Not yet recruiting NCT06179381 - Feeding the fAmiLy: the Intergenerational approaCh to fIght obesiTY (FACILITY)
Completed NCT05475951 - Gasdermin-D and Pannexin-1 in Pregnancy N/A
Active, not recruiting NCT04060381 - Myocardial Deformation Before and After Birth
Not yet recruiting NCT06245083 - Evaluating Pyrroloquinoline Quinone (PQQ) for Improving Obese Pregnancy Outcomes Early Phase 1